Plaque Psoriasis
📧 Sign up to get email alerts when something new happens for Plaque Psoriasis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2016-06-27Clinical Trial Update: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab [Phase 4]
Phase 4 trial updating etanercept treatment in patients with moderate to severe plaque psoriasis who lost response to adalimumab; study term…
-
CLINICAL_TRIALS trial_result · 2016-06-24Clinical Trial Update: Ammonium Lactate Lotion 12% (Lac-hydrin®) and Halobetasol Propionate Ointment 0.05% (Ultravate®) in the Treatment and Maintenance of Psoriasis [Phase 4]
Phase 4 clinical trial evaluating ammonium lactate 12% lotion (Lac-Hydrin) and halobetasol propionate 0.05% ointment (Ultravate) for the tre…
-
FDA approval · 2016-06-21FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental NDA for Taclonex (calcipotriene and betamethasone dipropionate) by LEO Pharma Inc.
-
FDA approval · 2016-06-20FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental application for ENSTILAR (calcipotriol and betamethasone dipropionate) submitted by LEO Pharma Inc.
-
CLINICAL_TRIALS trial_result · 2016-05-26Clinical Trial Update: Evaluation of Ixekizumab Using Auto-Injector or Prefilled Syringe in Participants With Moderate to Severe Plaque Psoriasis [Phase 3]
Phase 3 trial evaluating ixekizumab delivery via auto-injector or prefilled syringe in adults with moderate to severe plaque psoriasis has c…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2016-05-16Clinical Trial Update: Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis [Phase 2]
Phase 2 blinded study comparing a topical investigational lotion to an approved cream for plaque psoriasis has completed, with results poste…
-
FDA approval · 2016-05-12FDA Approved: BETAMETHASONE DIPROPIONATE — Supplemental Application (E. Fougera & Co. a division of Fougera Pharmaceuticals, LLC)
The FDA approved a supplemental application for Betamethasone Dipropionate from E. Fougera & Co., authorizing changes to the approved produc…
-
FDA approval · 2016-04-25FDA Approved: FLUOCINOLONE ACETONIDE OIL — Original Application (Rising Pharma Holdings, Inc.)
FDA approves Rising Pharma Holdings' Fluocinonide Acetonide Oil as a generic topical corticosteroid for inflammatory and pruritic skin condi…
-
FDA approval · 2016-04-15FDA Approved: CLOBEX — Supplemental Application (Galderma Laboratories, L.P.)
The FDA approved a supplemental application for CLOBEX (clobetasol propionate) from Galderma Laboratories, L.P. This action typically accomp…
-
CLINICAL_TRIALS trial_result · 2016-04-14Clinical Trial Update: A Study of Multiple Doses of AbGn-168H by Intravenous Infusion in Patients With Moderate to Severe Chronic Plaque Psoriasis [Phase 2]
Phase 2 study evaluating multiple intravenous doses of AbGn-168H in patients with moderate to severe chronic plaque psoriasis; the trial has…
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis [Phase 2]
Phase 2 trial evaluating the efficacy and safety of halobetasol propionate lotion 0.05% in plaque psoriasis has completed and results were p…
-
CLINICAL_TRIALS trial_result · 2016-04-11Clinical Trial Update: A Comparison of 000-0551 Lotion Versus Vehicle Lotion in Subjects With Plaque Psoriasis (Study -304) [Phase 3]
Phase 3 trial comparing 000-0551 Lotion to vehicle lotion in plaque psoriasis was completed and results have been posted.
-
FDA approval · 2016-04-05FDA Approved: INFLECTRA — Original Application (Pfizer Laboratories Div Pfizer Inc)
FDA approved INFLECTRA (infliximab-dyyb) as a biosimilar to infliximab for multiple autoimmune diseases, expanding access to a biologic ther…
-
FDA approval · 2016-03-22FDA Approved: TALTZ — Original Application (Eli Lilly and Company)
The FDA approved the original Biologics License Application for TALTZ (ixekizumab) from Eli Lilly for the treatment of plaque psoriasis in a…
-
FDA approval · 2016-03-18FDA Approved: TACLONEX — Supplemental Application (LEO Pharma Inc.)
FDA approved a supplemental application for Taclonex (calcipotriene and betamethasone dipropionate) from LEO Pharma Inc. This action may inv…
-
FDA label_change · 2016-03-08FDA Approved: ENSTILAR — Supplemental Application (LEO Pharma Inc.)
The FDA approved a supplemental labeling application for ENSTILAR (calcipotriene and betamethone dipropionate) from LEO Pharma Inc., resulti…
-
CLINICAL_TRIALS trial_result · 2016-03-08Clinical Trial Update: Safety and Efficacy Study of Etanercept (Qiangke®) to Treat Moderate to Severe Plaque Psoriasis [Phase 3]
This document provides an update on a Phase 3 clinical trial evaluating Etanercept (Qiangke) for safety and efficacy in moderate-to-severe p…
-
CLINICAL_TRIALS trial_result · 2016-03-01Clinical Trial Update: Safety and Tolerability Study of COVA322 in Patients With Stable Chronic Moderate-to-severe Plaque Psoriasis [Phase 1, Phase 2]
Safety and tolerability study of COVA322 in stable chronic moderate-to-severe plaque psoriasis was terminated after Phase 1/2, according to …
-
FDA approval · 2016-02-05FDA Approved: SERNIVO — Original Application (Primus Pharmaceuticals, Inc.)
FDA approved SERNIVO (betamethasone dipropionate) from Primus Pharmaceuticals in an original NDA for the topical treatment of plaque psorias…
-
CLINICAL_TRIALS trial_result · 2016-01-06Clinical Trial Update: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE)
This update reports a completed Spain-based study (PROMISE) evaluating adalimumab (HUMIRA) for moderate-to-severe chronic plaque psoriasis, …
-
CLINICAL_TRIALS trial_result · 2016-01-05Clinical Trial Update: Multiple-dose Regimen Study to Assess Effect of 12 Months of Secukinumab Treatment on Skin Response and Biomarkers in Psoriasis Patients [Phase 2]
Phase 2 trial evaluating a 12-month treatment with secukinumab in plaque psoriasis. The study assessed skin response and biomarkers and is r…
-
CLINICAL_TRIALS trial_result · 2015-12-31Clinical Trial Update: Efficacy Study Comparing Topical M518101 and Vitamin D3 in Adult Psoriasis Patients [Phase 3]
This document reports a Phase 3 efficacy trial comparing topical M518101 with Vitamin D3 for adults with plaque psoriasis. The trial has com…
-
FDA approval · 2015-12-21FDA Approved: OTEZLA — Supplemental Application (Amgen, Inc)
The FDA approved a supplemental application for OTEZLA (apremilast) from Amgen that updated its labeling.
-
CLINICAL_TRIALS trial_result · 2015-12-08Clinical Trial Update: Evaluate the Effect of Elimune Capsules [Phase 1]
Elorac's Phase 1 trial of Elimune Capsules for plaque psoriasis has completed, as indicated by the trial status.
-
CLINICAL_TRIALS trial_result · 2015-12-02Clinical Trial Update: LAS41008 in Moderate to Severe Chronic Plaque Psoriasis [Phase 3]
Phase 3 study LAS41008 for moderate to severe plaque psoriasis has completed, as reported in the clinical trial update from Almirall.